These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19147858)

  • 1. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
    Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
    Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
    J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
    Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
    Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
    Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
    J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
    Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
    J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor.
    Choo EF; Belvin M; Chan J; Hoeflich K; Orr C; Robarge K; Yang X; Zak M; Boggs J
    Xenobiotica; 2010 Nov; 40(11):751-62. PubMed ID: 20836753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
    Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.